Business
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.","length":706,"tagName":"p"},{"type":"text","content":"NanoViricides will be eligible for a Priority Review Voucher (PRV) upon approval of the drug if NV-387 is designated as a Rare Pediatric Disease Drug. A PRV carries immediate economic value. It is a tradable instrument, and recently has generally fetched around $160 million upon sale of the PRV to another company [1]. A PRV carries the benefit of accelerated approval of the drug for which it is used by the purchaser, which brings this value to the PRV.","length":456,"tagName":"p"},{"type":"text","content":""NV-387 as an effective drug is expected to be an important tool to fight Measles resurgence in the USA and worldwide, when approved," said Anil R. Diwan, PhD, adding, "Treating a Measles patient with NV-387 would help with rapid recovery and eliminate the high morbidity and the rare post-Measles ‘Immune Amnesia' effects."","length":348,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"NanoViricides","className":"","disableSlideshowImg":false,"size":{"original":{"width":950,"height":1255,"url":"https://media.zenfs.com/en/accesswire.ca/0f22e4b62a31ce3a6b13740f84227213"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Mx4FfbtHKet0YbXq5f7oHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEyNjg-/https://media.zenfs.com/en/accesswire.ca/0f22e4b62a31ce3a6b13740f84227213","width":950,"height":1255},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vYVdp.57Iy022vE7tvqpfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE5MDA7aD0yNTEw/https://media.zenfs.com/en/accesswire.ca/0f22e4b62a31ce3a6b13740f84227213","width":950,"height":1255}},"href":"...